Hypoxia-Activated Therapy for Solid Tumors with Checkpoint Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments that enhance immune responses often face limitations in efficacy and can lead to immune-related adverse effects, and there is a need for improved strategies to target solid tumors effectively.
Innovation Solution
A method involving the administration of a hypoxia-activated bioreductive agent (HABA) followed by hypoxia induction and an immune checkpoint inhibitor to enhance immune response against solid tumors, utilizing agents like tirapazamine and monoclonal antibodies to PD-1 or CTLA-4 to induce tumor necrosis and boost immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors are administered to enhance immune response against cancer, then immune-mediated anti-tumor activity is improved, but immune-related adverse effects worsen
Solution Approach 1:
The patent employs radiation therapy to induce localized tumor necrosis and immune cell infiltration specifically at the tumor site, rather than systemically activating the immune throughout the body. This localized approach enhances anti-tumor immunity where needed while minimizing systemic immune-related adverse effects. The radiation creates a localized immunogenic cell death that recruits immune cells to the tumor microenvironment without causing widespread immune activation.
Solution Approach 2:
The patent administers immune checkpoint inhibitors after radiation therapy has already induced tumor necrosis and immune cell infiltration. This preliminary action by radiation prepares the tumor microenvironment with necrotic debris and recruited immune cells, making the subsequent immune checkpoint inhibitor administration more effective at lower doses, thereby reducing immune-related adverse effects while maintaining anti-tumor efficacy.
2Ease of operation
If conventional immune therapy is used to treat cancer, then treatment simplicity is maintained, but therapeutic efficacy worsens
Solution Approach 1:
The patent combines radiation therapy with immune checkpoint inhibitor administration in a sequential treatment regimen. The radiation component induces tumor necrosis and immune cell infiltration, while the immune checkpoint inhibitor releases brakes on the activated immune cells. This combination leverages two established treatment modalities to achieve synergistic anti-tumor efficacy while maintaining relative treatment simplicity through a standardized sequential protocol.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves significant tumor necrosis and enhances immune response, potentially reducing tumor size to less than 50% of its initial size for at least 6 months with synergistic effects, minimizing side effects and improving treatment outcomes.
Implementation Method 1
administering a hypoxia-activated bioreductive agent (HABA); inducing hypoxia... to induce necrosis of the solid tumor
Data Source
AI summary
Disclosed herein are methods and compositions for enhancing an immune response to a solid tumor in a subject. In some embodiments, a method comprises: (a) administering to the subject a hypoxia-activated bioreductive agent (HABA); (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject or (ii) embolizing one or more blood vessels supplying the solid tumor; and (c) administering an immune checkpoint inhibitor prior to, simultaneously with, or subsequent to step (b) in an amount effective to enhance an immune response to the solid tumor, as compared to an immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.